ClearBridge Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

ClearBridge Investments’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,207	Closed	-$5K	–	1110
2019 Q2	$5K	Hold	1,207	–	–	﹤0.01%	1026
2019 Q1	$10K	Hold	1,207	–	–	﹤0.01%	994
2018 Q4	$10K	Hold	1,207	–	–	﹤0.01%	1013
2018 Q3	$9K	Buy	+1,207	New	+$8.11K	﹤0.01%	1059

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

ClearBridge Investments's BCRX Position: Q3 2019 in Review

ClearBridge Investments sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2019, closing a stake of 1,207 shares — an estimated $5K sold.

ClearBridge Investments first reported a position in BCRX in Q3 2018 and held it in 4 quarters. The position peaked at $10K in Q1 2019. 115 funds tracked by Wall St. Rank hold BCRX as of Q3 2019.

ClearBridge Investments reported no remaining BioCryst Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
ClearBridge Investments sold 1,207 BioCryst Pharmaceuticals shares in Q3 2019, an estimated $5K.
ClearBridge Investments first reported a position in BioCryst Pharmaceuticals in Q3 2018 and held it in 4 quarters.
ClearBridge Investments's BioCryst Pharmaceuticals position peaked at $10K in Q1 2019.
115 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2019.

Based on ClearBridge Investments's 13F filing for Q3 2019, filed 14 Nov 2019.